학술논문
268P Results from a real-world study of patients (pts) with hormone-receptor (HR)-positive HER2-negative metastatic breast cancer (MBC) treated with CDK4/6 inhibitors (CDK 4/6i) in three institutions
Document Type
Abstract
Author
Source
In Annals of Oncology September 2022 33 Supplement 7:S660-S660
Subject
Language
ISSN
0923-7534